Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 127 participants.

Also called NCT03847506

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 127 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03847506
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03847506. Randomized; quadruple masking; primary purpose treatment. Start 2018-07-05 (actual); primary completion 2020-12-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets
Acronym
REVERT-K
Condition
Hypertension, Hyperlipidemia
Intervention (Drug)
Ezetimibe/Rosuvastatin
Intervention (Drug)
Candesartan cilexetil/Amlodipine besylate
Intervention (Drug)
Candesartan cilexetil
Lead sponsor
HK inno.N Corporation (class: industry)

Record details

Record id
cardio:ct-nct03847506
Content hash
6b569776df8fbf8d67340f6d2f78a00cce74a08afab93d8df1ae9a10c8cf0569